EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.959
https://www.valueinhealthjournal.com/article/S1098-3015(23)04089-5/fulltext
Title :
EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04089-5&doi=10.1016/j.jval.2023.09.959
First page :
Section Title :
Open access? :
No
Section Order :
10452